Hengrui Medicine announced a few days ago that the company’s board of directors received the resignation report from Zhang Xiaojing, the company’s deputy general manager and chief medical executive officer (oncology). Zhang Xiaojing applied to resign from the company’s deputy general manager and chief medical executive (tumor) due to personal reasons. The resignation report will take effect from the date of delivery to the company’s board of directors. After resigning from the above position, Zhang Xiaojing no longer holds any position in the company, and the related work she is responsible for has been handed over. This personnel change will not affect the normal development of the company’s related work.
This article is reproduced from: https://finance.eastmoney.com/a/202212042578364243.html
This site is only for collection, and the copyright belongs to the original author.